The Ashton at Anderson Investor Presentation Fourth Quarter and Full Year 2025 March 11, 2026 SNDA NYSE Listed Forward-Looking Statements Explanatory Note As further described in the Company's Current Report on Form 8-K filed with the SEC on March 11, 2026, the Company completed its previously announced acquisition of CNL Healthcare Properties, Inc. ("CHP") through a series of steps ending with a forward merger of CHP with and into a subsidiary of the Company (the "CHP merger" or "merger"), with such subsid ...

ANI Pharmaceuticals FY Conference Summary Company Overview - **Company**: ANI Pharmaceuticals (NasdaqGM:ANIP) - **Focus**: Transitioning from a generics company to a leading rare disease company, with over 50% of revenues now derived from rare disease assets [3][6] Key Financial Highlights - **2025 Performance**: - Revenue growth of **44%** year-over-year - Adjusted non-GAAP EBITDA growth of **47%** - Rare disease business revenue: **$347 million**, a growth of **75%-76%** - Generics business revenue: **$384 million**, a growth of **28%** [6][7] - **2026 Guidance**: - Projected total company revenues: **$1 billion to $1.115 billion** - Projected adjusted non-GAAP EBITDA: **$275 million to $290 million** - Rare disease revenue expected to grow to **$540 million to $575 million** [7][8] Core Product Insights - **Cortrophin**: - Addressable patient population for acute gouty arthritis flares: **285,000** patients, with only **36%** receiving treatment and **8%** receiving injectable treatments [12] - Market growth potential is significant, with a focus on underpenetrated indications [12][13] - The ACTH market was valued at **$1.2 billion** in 2017 but declined to **$600 million** in 2021 due to external factors. The market is now recovering [27][28] - **ILUVIEN**: - Acquired to synergize with Cortrophin, focusing on ophthalmology - Expanded sales force to promote both Cortrophin and ILUVIEN [51] - Indicated for diabetic macular edema and chronic non-infectious uveitis, with a simplified product label [53] Competitive Landscape - **Cortrophin vs. Competitors**: - Difficult to genericize due to complex manufacturing processes and formulation differences [16][38] - ANI's growth has been driven by reaching new patients rather than just capturing market share from competitors [33] Strategic Focus - **Investment in R&D**: ANI invests a high single-digit percentage of generics sales into R&D, allowing for the launch of **10-15 new products annually** [61] - **Balance Sheet**: Leverage reduced to **2x**, with a focus on organic growth opportunities in rare disease and generics [75] Market Perception and Investor Feedback - There is a perceived disconnect between stock performance and the company's growth potential, particularly in the rare disease segment [79][82] - The company emphasizes the long-term growth potential of its rare disease portfolio and the durability of its assets [82] Conclusion - ANI Pharmaceuticals is positioned for significant growth in the rare disease market, with strong financial performance in 2025 and optimistic guidance for 2026. The company is focused on expanding its market presence while maintaining profitability and addressing investor concerns regarding the durability of its growth.

Summary of IP Strategy Holdings FY Conference Call Company Overview - **Company Name**: IP Strategy Holdings (NasdaqCM:IPST) - **Core Business**: The company is the first Nasdaq-listed entity to hold the IP token as its primary reserve asset and operates a validator on the Story Protocol, which is focused on intellectual property (IP) protection through tokenization [1][4][6]. Industry Context - **Industry Focus**: The discussion centers around the intellectual property sector, particularly in the context of challenges posed by AI and large language models (LLMs) that utilize copyrighted material without permission [4][15]. - **Market Size**: The intellectual property asset class is valued at approximately $80 trillion, indicating significant potential for blockchain applications in this area [15]. Key Points and Arguments - **Tokenization and IP Protection**: The Story Protocol is designed specifically for IP protection, allowing creators to register their works on-chain, set usage parameters, and ensure they are compensated for their creations [16][22]. - **Revenue Generation**: IP Strategy Holdings generates revenue through staking its IP tokens, with yields ranging from 10% to 20% annually. Additionally, a covered call strategy has yielded around 60% per year [11][36]. - **Acquisition Strategy**: The company is exploring the acquisition of IP-based assets, such as music catalogs and user-generated content, to enhance its portfolio and create a flywheel effect in the ecosystem [7][44]. - **Blockchain Advantages**: The Story Layer 1 blockchain is purpose-built for IP, allowing for efficient tracking and monetization of digital content, which is more effective than traditional methods [32][16]. Additional Insights - **Emerging Use Cases**: The ease of engaging with IP through blockchain is expected to stimulate new use cases, enabling everyday creators to interact with global IP more effectively [17]. - **Regulatory Environment**: The ongoing discussions in U.S. policy regarding the tokenization of assets may lead to a more favorable environment for blockchain applications in IP [56]. - **Competitive Landscape**: The company believes that the Story Protocol has the potential to become the industry standard for IP tokenization, supported by significant investments from major players in the field [30]. Conclusion - **Growth Potential**: IP Strategy Holdings is positioned for growth within the blockchain and IP sectors, leveraging its unique business model and the increasing importance of IP rights in the digital age [64].

Summary of GeneDx Conference Call Company Overview - GeneDx has been operating for 25 years, focusing on diagnosing rare diseases through whole exome and whole genome sequencing technology, which has been refined over two decades [2][4] Core Market Insights - The foundational markets include clinical geneticists and pediatric neurologists, each with approximately 2,000 specialists in the U.S. [5] - 80% of clinical geneticists order exome and genome tests from GeneDx, but they only utilize these tests for about one-third of their patients, indicating significant growth potential [6] - Pediatric neurologists have a lower penetration rate, with only about one-third ordering exome and genome tests, suggesting a long runway for growth [7] NICU Market Potential - GeneDx aims to order over 200,000 tests annually in the Neonatal Intensive Care Unit (NICU), with only 25% of NICUs currently active accounts [9] - Currently, only 5% of NICU patients receive genetic tests, but successful implementations, like Seattle Children's, show that up to 60% could benefit from such tests [9][28] Expansion Markets - GeneDx plans to expand into prenatal testing and general pediatricians, leveraging updated guidelines from the American Academy of Pediatrics [10][44] - The company has launched new products, including GenomeDx Prenatal, to tap into the prenatal market, which has a potential of 150,000 tests annually [48] Sales Strategy and Growth Projections - GeneDx is increasing its sales team from 50 to 75 representatives to enhance market penetration and improve utilization rates among existing accounts [20][22] - The company projects a volume growth of 33%-35%, with 25%-27% expected from foundational markets [24] Challenges and Education Efforts - The slow adoption of exome and genome testing among physicians is attributed to entrenched behaviors and the need for ongoing education about the benefits and advancements in genetic testing [12][14] - GeneDx is focused on dispelling myths about the complexity and cost of genetic tests, aiming to align turnaround times and costs with multi-gene panels [12][18] Customer Experience Enhancements - A new customer experience initiative is being developed to streamline the ordering process for general pediatricians, which is currently in beta testing [45] - The goal is to simplify the diagnostic process and provide tailored reports that are easier for non-expert physicians to understand [45] Conclusion - GeneDx is positioned for significant growth in the genetic testing market, with a focus on expanding its reach into new specialties and improving utilization rates among existing customers. The company is actively addressing challenges related to physician education and market penetration while enhancing customer experience to facilitate adoption.

Summary of MBX Biosciences FY Conference Call Company Overview - **Company**: MBX Biosciences (NasdaqGS:MBX) - **Industry**: Biotechnology, focusing on precision endocrine peptides (PEPs) for endocrine and metabolic diseases [4][5] Key Points and Arguments Platform Technology and Pipeline - MBX is pioneering PEPs aimed at improving the efficacy and duration of peptide therapeutics for endocrine and metabolic diseases [4] - The company has achieved a significant regulatory milestone with a successful end-of-phase 2 meeting with the FDA, allowing them to proceed to phase 3 trials for hypoparathyroidism (HP) [5] - The phase 3 trial is set to start in Q3 2026, focusing on a once-weekly PTH replacement therapy [5] Hypoparathyroidism Program - The phase 3 study will be placebo-controlled for 6 months, with a primary endpoint based on a responder rate and a key secondary endpoint of normalizing urine calcium [7][8] - The differentiation from competitors, such as Yorvipath, lies in the inclusion of urine calcium as a pre-specified endpoint [9][11] - Current standard of care for HP is considered outdated, with patients often managing their condition with multiple pills, leading to a high burden of treatment [11][12] - A once-weekly therapy is expected to significantly improve patient quality of life, as indicated by positive feedback from endocrinologists and patients [12][15] Market Opportunity - There is a strong unmet need in the HP market, with patients expressing a desire for a more manageable treatment regimen [11][12] - 80% of endocrinologists indicated they would switch patients from a daily to a weekly treatment if available, highlighting the potential for market expansion [15] Phase 2 Data and Comparisons - In the phase 2 Avail study, MBX reported a 63% response rate compared to placebo, with a significant increase to 79% in the open-label extension [16] - The placebo response rates were comparable to those seen in competitors, suggesting a robust treatment effect [16][19] Obesity Portfolio - MBX is expanding its portfolio into obesity treatments, starting with MBX 4291, a GLP-1/GIP co-agonist prodrug expected to offer once-monthly dosing with improved tolerability [5][27] - The obesity market is recognized as a major health issue with significant unmet needs, and MBX aims to lead in this field [27][28] - The company is focusing on reducing gastrointestinal side effects commonly associated with current obesity treatments [28][29] Upcoming Data and Expectations - The company plans to release one-year follow-up data from the phase 2 study at a major medical meeting in Q2 2026, which will include various biomarkers and safety data [22][25] - Expectations for the obesity program include demonstrating competitive weight loss and tolerability compared to existing treatments [33][34] Competitive Landscape - MBX's approach to treating post-bariatric hypoglycemia (PBH) with a long-acting GLP-1 antagonist is positioned to address a significant need in the market, differentiating itself from shorter-acting competitors [36][39] - The company emphasizes the importance of once-weekly administration for patient convenience and improved quality of life [39] Additional Important Insights - The PEP platform is designed to enhance the pharmacokinetics of peptide drugs, aiming for a slow rise to maximum concentration and reduced fluctuations, which is expected to improve tolerability [30][31] - The company has sufficient cash reserves to support operations and development through 2029, providing a strong foundation for advancing its programs [6]

Summary of Flagstar Financial Conference Call Company Overview - **Company**: Flagstar Financial (NYSE: FLG) - **Current Status**: The bank has reached a size of $90 billion and is focused on servicing major markets including California, Arizona, Florida, New York, New Jersey, Ohio, and Michigan [4][5] - **Profitability**: The bank returned to profitability in Q4 2025 after a challenging period [5][18] Strategic Goals - **Performance Target**: Aim to be in the top 25% of regional banks [5][6] - **Risk Culture**: Establish a strong risk culture within the organization [6] - **Customer-Centric Approach**: Strive to be the best customer-centric bank in America [6] Economic Outlook - **GDP Growth**: Expected growth of 2%-3% [9] - **Inflation**: Currently contained around 2.7% [9] - **Business Sentiment**: Positive outlook from business owners, with no negative feedback observed during recent customer interactions [10][12] Financial Performance - **CET1 Capital**: Ended Q4 with a CET1 capital ratio of 12.83%, the best among regional banks [15] - **Liquidity Position**: Access to $27 billion in cash and securities for immediate pledging [16] - **Expense Reduction**: Over $700 million in expenses cut to support growth initiatives [16] Commercial and Industrial (C&I) Business - **C&I Growth**: Generating approximately $2 billion in outstanding loans each quarter [5] - **Future Projections**: Potential to scale C&I originations to $10 billion per quarter [29] - **Loan Quality**: Average loan size of $25 million with a utilization rate of 70% [36] Commercial Real Estate (CRE) - **Payoffs**: Approximately $950 million in par payoffs for the quarter, with 40%-50% being substandard loans [43] - **New Lending**: Targeting $2 billion in new CRE loans this year, focusing on floating rates tied to SOFR [45] Net Interest Margin (NIM) and Profitability - **NIM Expansion**: Expected to improve as legacy loans mature and are replaced with higher-yielding loans [49] - **Targets**: Projected NIM range of 2.40%-2.60% for 2026-2027, with potential to reach 2.80%-2.90% [49] Hiring and Talent Acquisition - **Banker Recruitment**: Focus on hiring mid-career bankers with experience in OCC-regulated environments [24] - **Growth Strategy**: Building a strong regional bank by expanding the C&I book and enhancing product capabilities [26] Credit and Capital Management - **Credit Trends**: Positive outlook on reducing non-performing loans, with expectations for substantial reductions this year [59] - **Capital Strategy**: Management will assess capital needs based on profitability and loan growth before making decisions on excess capital [67] Market Position and Future Outlook - **Valuation Gap**: The bank is trading at a discount to book value, with potential for significant value creation over the next 18 months [19] - **Credit Rating Upgrade**: Recent upgrade to investment grade by Fitch, enhancing the bank's ability to gather deposits [71] Conclusion - **Overall Sentiment**: The management team expresses optimism about the bank's future, emphasizing the importance of executing their strategic plan to close the valuation gap and enhance shareholder value [70][76]

Summary of TD Bank Conference Call Company Overview - **Company**: TD Bank (NYSE: TD) - **Date**: March 11, 2026 - **Speaker**: Kelvin Tran, CFO Key Points Loan Growth - Canadian loan growth for Q1 2026 was strong, with mortgage business volume increasing by over 5% year-over-year despite a challenging market [4] - Credit card volume in Canada rose by 7% year-over-year, with active accounts at record levels, indicating future growth potential [5] - Business loans increased by 6% year-over-year, showing resilience in a volatile macro environment [10] - In the U.S., core loan growth was 2% year-over-year, excluding runoff portfolios, aligning with market trends [11] Net Interest Margin and Loan Spreads - Loan spreads are improving, with a disciplined approach to return on equity (ROE) thresholds for issuing loans [12] - Recent trends suggest that fewer rate cuts in the U.S. could positively impact margins [13] Deposit Trends - There has been a consistent decline in term deposits, shifting towards core deposits, which is favorable for margins [16] Cost Management - TD Bank is focused on cost reduction, targeting CAD 2 billion to CAD 2.5 billion in savings through various levers, including restructuring and automation [24] - A significant restructuring charge of CAD 775 million was noted, with CAD 400 million in expected cost savings reaffirmed [22][24] Credit Quality and Provisions for Credit Losses (PCL) - The PCL ratio is guided at 40-50 basis points for the year, down from 45-55 basis points last year, indicating improved credit quality [39] - The bank is comfortable with a coverage ratio of 99 basis points, which includes CAD 500 million reserved for tariff and trade policy-related risks [40] Capital Management - TD Bank aims for a Common Equity Tier 1 (CET1) ratio of 13% by the second half of 2027, with a focus on driving ROE growth to 16% by 2029 [61][62] - The bank has committed to returning CAD 7 billion in capital to shareholders this year [57] Wholesale Banking and TD Cowen Integration - Strong momentum in wholesale banking, with Q1 earnings of CAD 560 million, up 65% year-over-year, and record revenue of CAD 2.5 billion [70] - The integration of TD Cowen is seen as beneficial, filling gaps in advisory services and enhancing client relationships [87] Credit Card Business Developments - The proprietary bank card business in the U.S. grew by 15% year-over-year, with a strategic focus on partnerships like Nordstrom to enhance scale and profitability [92][97] - The bank is now taking over servicing Nordstrom's clients, which is expected to increase revenue and share of credit risk [96][102] Conclusion - TD Bank is committed to executing its strategies as outlined during the Investor Day, focusing on loan growth, cost management, and capital returns to shareholders [105]

Summary of Pacira BioSciences FY Conference Call Company Overview - **Company**: Pacira BioSciences (NasdaqGS:PCRX) - **Key Products**: EXPAREL, ZILRETTA, iovera - **Strategic Plan**: Five by Thirty strategy aiming for 3 million patients by 2030, double-digit top-line growth, 5-point margin expansion, 5 pipeline products, and 5 partnerships [2][3] Core Insights and Arguments - **NOPAIN Act Implementation**: - Launched in January 2025, providing reimbursement for EXPAREL outside of bundled payments at ASP + 6% for Medicare patients [4][19] - Expanded coverage to commercial payers, achieving up to ASP + 29% [4][20] - 102 million lives covered outside the bundle by year-end [4] - Positive impact on opioid utilization expected due to the NOPAIN Act [20][22] - **Volume Growth**: - EXPAREL experienced over 6% volume growth in 2025, up from 3% the previous year [15] - Anticipated steady increase in volume and revenue convergence in the second half of 2026 as GPO contracts are fully realized [17][27] - **Financial Guidance for 2026**: - Total company revenue expected to grow 3%-6%, with EXPAREL projected to grow 4%-8% [23] - Emphasis on execution and expanding payer coverage to achieve higher revenue targets [27] - **Partnerships**: - Significant agreements with Johnson & Johnson MedTech to enhance ZILRETTA's market reach and with LG Chem for EXPAREL and ZILRETTA in Asia Pacific [5][50] - Focus on building partnerships in Europe and Latin America to expand market presence [50] Pipeline Developments - **PCRX-201**: - Potential game-changing gene therapy for osteoarthritis, with promising phase 1 results and phase 2 part A results expected by year-end [60][66] - RMAT designation received to accelerate development [65] - **ZILRETTA and iovera**: - Anticipated growth driven by the J&J partnership and dedicated sales forces for each product [39][25] - Upcoming data events for ZILRETTA and iovera expected to provide further insights into their market potential [40] Additional Important Points - **Operational Efficiency**: - Improved margin from 76% due to better inventory management and reduced waste [43] - Continuous improvement in processes expected to support margin expansion [45] - **Market Awareness**: - High awareness of NOPAIN among healthcare professionals, with about half taking action to manage patients differently [21] - Ongoing claims analysis to support the positive impact of NOPAIN on patient outcomes and healthcare costs [22] - **Financial Position**: - Strong financial health with low leverage and capacity for accretive deals [77] - Focus on disciplined capital allocation to enhance growth [76] This summary encapsulates the key points discussed during the Pacira BioSciences FY Conference Call, highlighting the company's strategic initiatives, financial outlook, and product pipeline developments.

Summary of DeFi Technologies FY Conference Call Company Overview - **Company**: DeFi Technologies (NasdaqCM: DEFT) - **Industry**: Decentralized Finance (DeFi) and Digital Assets - **Key Executives**: Andrew Forson (President and Chief Growth Officer), Curtis Schlaufman (Vice President of Marketing and Communications) Core Business Model - DeFi Technologies is positioned as a vertically integrated digital asset platform, not just an ETP provider, encompassing various segments such as Valour, Stillman Digital, OTC and liquidity provisioning, DeFi Alpha, and Reflexivity Research [2][6][8] - The company aims to facilitate the connection between decentralized finance and traditional capital markets, leveraging stablecoins and digital assets [6][7] Financial Performance - Valour, the ETP platform, achieved record net inflows of $107 million in 2025 despite market volatility [11] - The company generates 5%-7% revenue on assets under management (AUM) from Valour, with additional revenue from other business lines [9][10] - AUM reached an all-time high of approximately $1.2 billion in August 2025, with consistent net inflows year-over-year [14][15] Market Strategy and Product Development - DeFi Technologies plans to launch institutional-focused products, including a UCITS fund with spot crypto underlying, targeting institutional capital [21][22] - The company is expanding its ETP offerings and exploring geographic expansion into Latin America, Africa, and Asia [22][27] - The focus is on protocols generating significant revenue and user growth, with a potential consolidation in the market [20] Regulatory Environment - Regulatory clarity, particularly from the U.S. Clarity Act, is expected to increase demand for DeFi's products, benefiting AUM and asset prices [30][31] - The company is positioned to capitalize on regulatory developments, enhancing its total addressable market [30] Stillman Digital - Stillman Digital, DeFi's OTC trading and liquidity provisioning platform, is projected to grow at a 20% year-over-year rate for 2026 [34] - The platform has completed over $60 billion in transactions, demonstrating its market agnosticism and ability to attract institutional clients [36][37] - Stillman Digital's services are applicable globally, with ongoing efforts to expand into new jurisdictions [34][36] Venture Portfolio - DeFi Technologies is investing in companies like Neuronomics, which leverages AI for trading strategies, and Stablecorp, launching Canada's first regulated stablecoin [39][43] - The integration of AI and machine learning into asset management is expected to enhance product offerings and generate consistent returns [42] Conclusion - DeFi Technologies is positioned as a strong player in the DeFi space, with a diversified revenue model and a focus on growth through regulatory clarity and product innovation [47][48] - The company emphasizes its ability to operate profitably and at scale while being risk-averse, with passive and recurring revenue streams [47]

Kyntra Bio Conference Call Summary Company Overview - **Company Name**: Kyntra Bio (formerly FibroGen) - **Ticker**: NasdaqGS:FGEN - **Event**: 2026 Conference on March 11, 2026 Key Highlights Company Transformation - Kyntra Bio transitioned from FibroGen to enhance impact for patients and shareholders [2] Financial Developments - Completed the sale of FibroGen China to AstraZeneca for approximately $220 million, including $135 million in cash [3] - Paid off a $75 million term loan facility and extended cash runway into 2028 [3] Product Pipeline FG-3246 and FG-3180 - FG-3246 is a potential first-in-class therapy targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) [4] - FG-3180 is a PET imaging agent in clinical development for patient selection [4] - Phase II trial for FG-3246 has commenced, focusing on mCRPC patients [5] Roxadustat - Roxadustat is a phase III-ready treatment for anemia associated with lower risk myelodysplastic syndrome (MDS) [5] - Approved in over 40 countries for anemia related to chronic kidney disease [5] - Kyntra Bio owns Roxadustat in North America, South America, and Australia [5] Clinical Trials and Data FG-3246 Phase 1 Results - Phase 1 trial showed an rPFS of 8.7 months and a 36% PSA50 response rate in heavily pretreated mCRPC patients [17] - Notable adverse events included 36% grade three or above neutropenia and 34% peripheral neuropathy [18] FG-3246 and Enzalutamide Combination - Phase 1B/2 trial showed 7 months rPFS across the entire cohort and 10.1 months for patients who progressed on one prior ARPI [21] - Strong correlation between CD46 tumor uptake and PSA50 response [23] Regulatory and Market Opportunities - Received orphan drug designation from the FDA for myelodysplastic syndrome, providing seven years of regulatory exclusivity upon approval [6] - Roxadustat aims to address unmet needs in lower risk MDS, with a focus on patients requiring 4 or more RBC units [31][36] - The worldwide MDS market is projected to exceed $4 billion in the next five years, presenting a significant commercial opportunity [38] Strategic Focus - Kyntra Bio is exploring multiple lines of therapy in prostate cancer and aims to leverage the unique properties of FG-3246 and FG-3180 [29] - The company is committed to developing Roxadustat as an oral alternative for elderly patients with MDS, addressing convenience and efficacy across different patient populations [37] Conclusion Kyntra Bio is positioned to capitalize on significant opportunities in oncology and hematology, with a robust pipeline and strategic focus on addressing unmet medical needs in mCRPC and lower risk MDS. The company is actively advancing its clinical trials and regulatory strategies to enhance its market presence and shareholder value.